Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 9/20 | 0.52 |
| ▸ | PTGES | O14684 | 1/20 | 0.50 |
| ▸ | CCR9 | P51686 | 4/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4086421 | 0.87 | MAPT (0.48) | PTGESGRIN1GRIN2B | |
| SCHEMBL4092463 | 0.79 | CCR2 (0.55) | CCR2PTGESCCR9ABCB11 | |
| SCHEMBL4104997 | 0.77 | CCR2 (0.53) | CCR2PTGESCCR9ABCB11 | |
| SCHEMBL4093522 | 0.76 | CCR2 (0.53) | CCR2CCR9ABCB11 | |
| SCHEMBL7682483 | 0.73 | CCR2 (0.58) | CCR2ABCB11 | |
| SCHEMBL4648818 | 0.73 | CCR2 (0.53) | CCR2CCR9PPARG | |
| SCHEMBL4096233 | 0.73 | CCR2 (0.57) | CCR2CCR9ABCB11 | |
| SCHEMBL3198946 | 0.73 | CCR2 (0.71) | CCR2CCR9ABCB11PPARG | |
| SCHEMBL4086498 | 0.71 | TP53 (0.46) | CCR2CCR9ABCB11 | |
| SCHEMBL4093410 | 0.69 | TP53 (0.44) | CCR2PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069384-A1 | THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069384-A1 | THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION | NPY5R, TH, PTGES | CCR2 1118/4885PTGES 3/4885CCR9 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.